The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > BUSINESS
BUSINESS
- Santen Profits Tumble Over 70% on Strong Yen, Divestment; Ophthalmology Biz Brisk
November 4, 2016
- Pfizer Japan Calls Off Transfer of Innovative Drugs after Global Split Plan Scrapped
November 4, 2016
- Mitsubishi Tanabe Licenses Cell Therapy Agent for Knee Osteoarthritis from S. Korean Firm
November 4, 2016
- Mitsubishi Tanabe Ekes Out Sales Rise on Simponi, Other Major Products
November 2, 2016
- Harvoni Top-Seller Drug in Japan in July-September: QuintilesIMS
November 2, 2016
- Strong Yen Dampens Sales of 4 Japanese Majors, but Global Brands Keep Up Momentum
November 2, 2016
- HER2-Targeting ADC Is One of Our Top Priorities: Daiichi Sankyo CEO
November 2, 2016
- Eisai’s Midterm Strategy Focusing on Neurology, Oncology “Gradually Producing Results”: CEO Naito
November 2, 2016
- Shionogi Shooting for New Product Sales of 200 Billion Yen in FY2020
November 2, 2016
- Takeda Establishes Drug Discovery Company in New York in Partnership with US Research Institutions
November 2, 2016
- Hisaharu Hirai Named as Japan Vaccine Chairman
November 2, 2016
- Merck Serono Aims to Get Japan Nod for Avelumab in 2017: Pres. Lee
November 2, 2016
- Takeda Mum on Kaketsuken Biz Transfer; CEO Says He Needs to Better Understand Situation
November 1, 2016
- MSD Files Japan NDA for Bezlotoxumab for C. Difficile Infection
November 1, 2016
- Pfizer Seeks Japan Approval of Breast Cancer Drug Palbociclib
November 1, 2016
- Eisai’s BACE Inhibitor Enters PIII, Enrollment Begins in US
November 1, 2016
- Nichi-Iko Wins Patent Suit over Elplat
November 1, 2016
- Shionogi Nets 12.2% Sales Rise on HIV Med Royalty Revenues
November 1, 2016
- Daiichi Sankyo Earnings Lower on Yen Moves; Olmesartan Suffers 21.8% Slide
November 1, 2016
- Forex Moves Drag Down Eisai’s Half-Year Sales despite Bullish Global Brands
November 1, 2016
ページ
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…